Cargando…
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)
PURPOSE: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas. Combining Hsp90 inhibitors to enhance endoplasmic reticulum stress with mTOR inhibition results in dramatic MPNST shrinkage in a genetically engineered MPNST mouse model. Ganetespib is an injectable poten...
Autores principales: | Kim, AeRang, Lu, Yao, Okuno, Scott H., Reinke, Denise, Maertens, Ophélia, Perentesis, John, Basu, Mitali, Wolters, Pamela L., De Raedt, Thomas, Chawla, Sant, Chugh, Rashmi, Van Tine, Brian A., O'Sullivan, Geraldine, Chen, Alice, Cichowski, Karen, Widemann, Brigitte C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013290/ https://www.ncbi.nlm.nih.gov/pubmed/32089640 http://dx.doi.org/10.1155/2020/5784876 |
Ejemplares similares
-
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
por: Widemann, Brigitte C., et al.
Publicado: (2019) -
Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies
por: Kim, AeRang, et al.
Publicado: (2017) -
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors
por: Higham, Christine S., et al.
Publicado: (2017) -
Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is
por: Liao, Sida, et al.
Publicado: (2018) -
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
por: Chugh, Rashmi, et al.
Publicado: (2020)